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Single nucleotide polymorphisms (SNP) in the human VMAT1 gene (SLC18A1) have 
been associated with schizophrenia in three different populations: Han Chinese, Western European 
and Japanese.  Effects of these mutations on transport function of the hVMAT1 protein have not 
been reported.  The goal of this study was to investigate functional and biochemical differences in 
human VMAT1 proteins with a threonine or proline at amino acid position 4 (Thr4Pro) and a 
serine or threonine at position 98 (Ser98Thr). COS1 cells were transfected with variant SNPs 
 
 
 
 
coding for 4Thr/98Ser, 4Pro/98Ser, or 4Thr98Thr.  Western blotting demonstrated robust over 
expression of the genes and no differences in electrophoretic mobility of the proteins.  Maximal 
transport of serotonin by the VMAT1 protein with 4Pro/98Ser was less than that of the 4Thr/98Ser 
or the 4Thr/98Thr.  Response of the 4Pro/Ser98 to the VMAT inhibitor reserpine was lower than 
that of the 4Thr/98Thr.  These findings suggest mechanisms for human VMAT1 links to 
schizophrenia.
 
 
 
 
 
 
Introduction 
 
A Brief Background on Vesicular Monoamine Transporters 
Vesicular monoamine transporters (VMATs) are 55 kD transport proteins that are 
embedded in the membranes of intracellular vesicles (5;27).  VMAT proteins are members 
of the Solute Carrier gene family (SLC18) that transport monoamines such as 
norepinephrine, dopamine, and serotonin into storage vesicles to allow subsequent release 
of the vesicle contents into a synapse or other extracellular space (10).   Two major 
VMATs, VMAT1 and VMAT2, are 60% identical in terms of their amino acid sequences.  
VMAT1 (known as the chromaffin granule amine transporter) is found in extraneural 
tissues including the chromaffin cells of the adrenal medulla and endocrine and paracrine 
cells of the GI tract.  VMAT2 (known as the synaptic vesicular monoamine transporter) is 
primarily located in neuronal cells of the central, peripheral and enteric nervous systems 
(8;19).  By accumulating newly synthesized neurotransmitter molecules and freshly 
returned neurotransmitters from the synapse, VMAT2 plays a critical role in the various 
signaling processes between monoamine neurons (18).  VMAT1 serves a similar role in 
adrenal medulla and neuroendocrine cells.  
Although VMAT2 is the major VMAT in human and rodent brain (8;19), Karen 
Brennan-Ashe of the Stewart lab at Virginia Commonwealth University detected VMAT1 
mRNA in the mouse medulla oblongata with the reverse transcriptase polymerase chain 
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reaction (RT-PCR) (1).   The novel finding of VMAT1 in human post mortem brain by 
Lohoff et al. with RT-PCR and Western Blots further increased interest in the localization 
of VMAT1 in the human brain (13).  The highest levels of human VMAT1 were identified 
in the substantia nigra, amygdala and hippocampus (13).  
 
A Look At How VMATs Work 
 Like plasma membrane transporters such as the dopamine transporter (DAT), 
serotonin transporter (SERT), and norepinepherine transporter (NET), VMATs display a 
similar size and topography with 12 transmembrane domains and both C-terminal and N-
terminals tails in the vesicle’s interior (11;17), and Figure 2).  Vesicular monoamine 
transporters differ from other membrane transporters in several ways.  Most importantly, 
VMAT utilizes a proton gradient energetically to transport substrates rather than the 
Na+/K+ gradient used by DAT, SERT, and NET (25).  The proton gradient is established 
across the vesicular membrane, which is created by a vacuolar ATPase (not directly 
associated with the transporter) in its antiport activity, exchanging two protons for each 
monoamine taken into the vesicle (22).  Once the first proton is bound to the transporter, a 
conformational change exposes a high affinity binding site.  Binding of the second proton 
causes the monoamine to be transported into the vesicular space (26).  During an action 
potential, vesicles move to the cell membrane and contents of the vesicle are discharged 
into the extracellular space by exocytosis (10). 
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The Link Between VMAT and Schizophrenia 
 Human VMAT1 is located on chromosome 8.  There are 484 annotated genes 
located on 8p 21-22; many of which are proto-oncogenes and tumor-suppressor genes (24).  
This region of the genome also is one of the regions most implicated for susceptibility to 
schizophrenia and bipolar disorders.  Roughly 8.5% of the genes contained on 8p are 
believed to contribute to neuropsychiatric disorders such as schizophrenia, autism, bipolar 
disorders and depression (12).  They are also implicated in neurodegenerative disorders 
such as Parkinson’s and Alzheimer’s disease (24).    
A number of single nucleotide polymorphisms (SNP) have been identified in the 
human Vmat1 gene (SLC18A1), SNPs are DNA sequence variations that occur when a 
single nucleotide (A, T, G or C) differs among members of a species, and geneticists are 
particularly interested in whether SNPs in human genes are more common in individuals 
with a specific disorder.   
Based on the Vmat1 gene location on chromosome 8, Bly tested the hypothesis that 
a VMAT1 SNP is associated with schizophrenia.  Sequenced DNA from post-mortem 
brain tissue of schizophrenic Caucasians revealed a statistically significant association with 
a homozygous SNP in exon 3 of the SLC18A1 gene.  This single base change, A277C 
(numbering based on GenBank Accession # NM_003153.3), resulted in a single amino 
acid change in the primary sequence of VMAT1 that produced a proline rather than a 
threonine at amino acid 4.  The CC genotype coding for the proline was observed in 21.4% 
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of the schizophrenic group compared to 2.6% in the control group (2).   This finding was 
supported by identification of the same SNP linked to schizophrenia in a Han Chinese 
population (3).  Additionally, two other laboratories have reported statistically significant 
associations of this and other SNPs of the Vmat1 gene with either schizophrenia or bipolar 
disorder in populations of European and Japanese descent (14;20).  Three SNPs in the 
coding region of the human Vmat1 gene that have been associated with schizophrenia are 
listed in Table 1.  A partial sequence of the VMAT1 cDNA NM_003053 illustrating the 
position of SNPs in the coding region is shown in Figure 1.  The predicted structure of the 
human VMAT1 protein is shown in Figure 2.  
 
Table 1.  Single Nucleotide Polymorphisms In The Human VMAT1 gene SLC18A1 
*SNP ID +NM_003053.3 
Bases & 
NP_003044.1 
Amino Acids 
SNP Alleles Major SNP 
Allele 
Major 
RNAAmino 
Acid 
rs2270641  A277C   Thr4 Pro T/G T AThr 
rs2270637 G560C   Ser98Thr C/G C GSer 
rs1390938 T674C    Thr136Ile A/G G CThr 
*SNP ID from the NCBI SNP data base and + GenBank Accession Numbers  
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                 C  
 268 ATG CTC CGG ACC ATT CTG GAT GCT CCC CAG CGG TTG CTG AAG GAG GGG AGA GCG TCC CGG 
M  L   R  P/T  I   L   D   A   P   Q   R   L   L   K   E   G   R   A   S   R    
 
  328 CAG CTG GTG CTG GTG GTG GTA TTC GTC GCT TTG CTC CTG GAC AAC ATG CTG TTT ACT GTG   
Q   L   V   L   V   V   V   F   V   A   L   L   L   D   N   M   L   F   T   V  
 
  388 GTG GTG CCA ATT GTG CCC ACC TTC CTA TAT GAC ATG GAG TTC AAA GAA GTC AAC TCT TCT   
 V   V   P   I   V   P   T   F   L   Y   D   M   E   F   K   E   V   N   S   S    
 
  448 CTG CAC CTC GGC CAT GCC GGA AGT TCC CCA CAT GCC CTC GCC TCT CCT GCC TTT TCC ACC   
 L   H   L   G   H   A   G   S   S   P   H   A   L   A   S   P   A   F   S   T 
                                                                     C 
  508 ATC TTC TCC TTC TTC AAC AAC AAC ACC GTG GCT GTT GAA GAA AGC GTA CCT AGT GGA ATA 
 I   F   S   F   F   N   N   N   T   V   A   V   E   E   S   V   P S/T  G   I 
   
  568 GCA TGG ATG AAT GAC ACT GCC AGC ACC ATC CCA CCT CCA GCC ACT GAA GCC ATC TCA GCT   
 A   W   M   N   D   T   A   S   T   I   P   P   P   A   T   E   A   I   S   A  
                                                                   T  
  628 CAT AAA AAC AAC TGC TTG CAA GGC ACA GGT TTC TTG GAG GAA GAG ACT ACC CGG GTC GGG   
 H   K   N   N   C   L   Q   G   T   G   F   L   E   E   E  T/I  T   R   V   G 
   
  688 GTT CTG TTT GCT TCA AAG GCT GTG ATG CAA CTT CTG GTC AAC CCA TTC GTG GGC CCT CTC   
 V   L   F   A   S   K   A   V   M   Q   L   L   V   N   P   F   V   G   P   L 
 
Figure. 1. Partial Sequence of NM_003053 (SLC18A1) with variants. Numbers are 
initial base numbers of codons of VMAT1 mRNA (GenBank Accession # NM_003053. 
Letters below the codons are standard amino acid abbreviations. Polymorphisms are 
highlighted in yellow, and the alternate base is above the codon.    
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Figure 2. Structure of the human VMAT1 protein predicted with  
 
 
 
 
 
 
 
 
 
Figure 2.  Predicted structure of the human VMAT1 protein.  HMMTOP software 
(http://www.enzim.hu/hmmtop/html/document.html) was used to generate the structure 
from the translated protein sequence NP_003044.1 = protein coded by NM_003053 
mRNA. 
 
 Evidence is compelling for association of these SNPs shown in Figure 1 with 
psychiatric disorders, butt there is no information on functional consequences of any of 
these SNPs.   As shown in Figure 2, amino acid 4 is located in the N-terminal cytoplasmic 
tail of the transport protein, and amino acids 98 and 136 are located in the first intra-
vesicular loop. Both cytoplasmic and intravesicular regions are postulated to interact with 
SER98THR 
ILE136THR 
THR4PRO 
LUMEN 
CYTOPLASM 
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substrates and inhibitors (16;23), but specific effects of the amino acid changes on 
VMAT1 transport activity are not known.  The goal of this study was to address this 
question by creating specific mutations in the human VMAT1 gene, transfecting the genes 
into COS1 cells and evaluating effects on the transport activity of protein expressed in the 
cells.  The initial reference gene used in this study coded for the haplotype Thr4 Ser98 
Ile136.  This haplotype was chosen as the reference based on genetic evidence that the 
alternate alleles are associated with schizophrenia or related disorders.  The 4Pro and 
Thr98 are linked to schizophrenia (2;3;14;20), and the 136 Ile is associated with partial 
protection against bipolar disorder (13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10 
 
 
Materials and Methods  
Cells 
The COS-1 kidney fibroblast cell line was obtained from American Type Culture 
Collection (ATCC # 30-2002, Manassas, VA). Cells were maintained at 37° C with 5% 
CO2 in DMEM medium (# 30-2002, ATCC) containing 4 mM L-glutamine, 4.5 g/L 
glucose and 1.5g/L sodium bicarbonate. COS-1 medium is supplemented with 10% heat 
inactivated fetal bovine serum, 100 units/ml penicillin and 100 units/ml streptomycin. 
 
Site-directed mutagenesis 
The VMAT1 clone with the reference sequence coding for 4Thr/98Ser/136 Ile was 
obtained from Origene - SC122643 in the pCMV6-Neo vector.  Primers designed by our 
research team and used for mutagenesis by the VCU Molecular Laboratory are shown in 
Table 2.  Variant genes were inserted into expression vectors, amplified in E.coli (end A- 
and Rec A-) and the plasmids purified in megapreps by the VCU Molecular Biology Core. 
Incubations were at 30 º C as recommended by Origene.  Full length sequencing by 
Operon (Huntsville, AL) verified all mutations and absence of recombination during 
cloning. 
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Table 2. Mutagenesis Primers 
 
Amino 
Acid 
Change to  
Sense (S)/Antisense (AS) 
4 Pro    S ATCACCATGCTCCGGCCCATTCTGGATGCTC/ 
          AS GAGCATCCAGAATGGGCCGGAGCATGGTGAT. 
98 Ser  S GTTGAAGAAAGCGTACCTACTGGAATAGCATGGATGAATG/ 
         AS CATTCATCCATGCTATTCCAGTAGGTACGCTTTCTTCAAC. 
 
 
 
Cell Transfection 
 To examine VMAT1 expression, COS-1 kidney fibroblasts were transfected with 
the VMAT1 cDNA according to the protocol of Finn et al. (9). Cells were grown to 
confluence in T-75 flasks (CoStar, Fisher Scientific) and fed 24 hours prior to 
electroporation.  In preparation for electroporation and transfection, cells were rinsed with 
calcium-free/magnesium-free phosphate buffered saline (PBS) and detached with 0.25% 
trypsin and 0.03% EDTA.  Cells were returned to medium containing serum to inactivate 
the trypsin and pelleted by centrifugation at 500 x g for 10 minutes at 4 °C.  The cells were 
resuspended in 800 µl of pre-warmed PBS containing calcium and magnesium 
(Invitrogen).  The cell suspension and 15 µg of DNA were transferred to a 0.4 cm gap 
cuvette in the gene Pulser II (Biorad, Hercules, CA) and electroporated at 0.4 kV and 975 
µF.  Cells were plated in T-75 flasks and incubated for three-4 days prior to preparation of 
membranes for transport assays or lysis for western analysis.  The expression vector has a 
neomyocin resistance gene, and cells incorporating the plasmid were selected by growth in 
medium with geneticin (500 µg/ml). 
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Membrane Preparation 
On the fourth day after electroporation, COS-1 cells from each T-75 flasks were 
rinsed with PBS, detached and pelleted with centrifugation as described above.  The pellet 
was washed twice in PBS, centrifuged after each wash and resuspended in 200 µl of 
sucrose-Hepes buffer (SH) containing 0.32 M sucrose in 10 mM Hepes adjusted to pH 7.4 
with 1 M KOH and supplemented with proteolytic inhibitors (2 ug/ml aprotinin and 
leupeptin 1 ug/ml pepstatin A and E-64, and  0.2 mM phenylmethylsulfonylfluoride 
(PMSF).  The suspension was transferred to a 1.5 ml tube and homogenized by sonication 
at 4 pulses, 0.5 seconds per pulse, to yield approximately 3 Watts power.  After the 
suspension was centrifuged at 500 x g for 10 minutes at 4 °C, the supernatant was 
immediately removed to a tube on ice.  Total protein was measured with the Bio-Rad 
protein assay (Bio-Rad Laboratories, Hercules, CA).  Aliquots of the supernatant were 
stored at – 70 °C until assayed for VMAT activity.   
Western Blotting 
Membrane proteins were separated by electrophoresis on 10% polyacrylamide gels 
and transferred to nitrocellulose. Blots were incubated for an hour at 24 ˚C in blocking 
solution containing Tris Buffered Saline (TBS) and 3% dry milk, and then incubated 
overnight at 4 C with primary goat anti-human VMAT1 antibody C-19 (#SC-7718, Santa 
Cruz Biotechnology, Santa Cruz, CA) diluted 1:200 in TBS + 0.1% Tween-20 (TBST).   
Blots were washed with TBST and incubated for an hour at 24 °C with 1:10,000 donkey 
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anti-goat  IgG-horseradish peroxidase  (Santa Cruz).  The blots were visualized with 
enhanced chemiluminesence (Amersham, Biosciences, UK). 
 
VMAT Uptake Assay 
 Each assay tube contained 50 µg of cell protein, 5 mM ATP,  0.25 mM ascorbic 
acid, and 20 nM radiolabeled serotonin (3H-5HT) = 5-H[G-3H]T creatine sulfate 27 Ci / 
mmol (American Radiolabeled Chemicals, Saint Louis, Mo), except in saturation 
experiments in which increasing concentrations of labeled + unlabeled serotonin were 
incubated to achieve saturation.  Reactions were in a total volume of 200 µl of uptake 
buffer.  Incubations were conducted at 27°C for 5 minutes, except in time course 
experiments or in saturation assays in which incubation was for 1.5 min to approximate 
initial velocity of transport.  The reaction was terminated by addition of 1 ml cold SH 
buffer, rapidly filtered through 0.2 µm Supor 200 membranes (Pall/Gelman # 60300), and 
washed with twice with 1 ml of cold SH buffer in a Millipore sampling manifold. Filters 
were transferred to 10 ml of Scintisafe 50% Plus scintillation fluid (Fisher Scientific,) and 
radioactivity was measured with a Beckman LS6000IC scintillation counter.   
 
Statistics 
 Statistical analyses were as follows:  For comparisons of VMAT1 activity at 
various time points, a split-plot two-way analysis of variance (ANOVA with groups as 
between-subjects factor and time as the within-subjects factor) and Newman Keuls’ post-
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hoc tests were used.  For comparison of activity measured at 5 min a one-way ANOVA 
and Newman Keul’s post hoc was used.  For transport kinetics and inhibition curves, best 
fit non-linear regressions were performed on data from 3 different transfections of each 
variant, and significant differences were determined from the 95% confidence limits of the 
regressions.  ANOVAs and non-linear regressions were performed with GraphPad Prism 5.   
(GraphPad Software, Inc., La Jolla, CA).  
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Results 
 
Expression of hVMAT1 Variants in Transfected Cells 
 Western blotting confirmed expression of hVMAT1 variants in COS1 cells 
transfected with hVMAT1 gene variants (Fig. 3).  As shown in Fig. 3, loading of only 2 µg 
of total protein was sufficient to observe marked immunoreactiveVMAT1 protein bands at 
63 and 29 Kd .  There were no differences in electroporetic mobility of the proteins on 
gels. The translated hVMAT1 protein sequence NP_003044.1 consists of 525 amino acids 
and a molecular size of 56 Kd (calculated with the Science Gateway Protein Molecular 
Weight Calculator at  http://www.sciencegateway.org/tools/proteinmw.htp), but the major 
imunoreactive  hVMAT1 proteins observed were 63 and 29 Kd.   The 63 Kd size is 
consistent with evidence for phosphorylation and glycosylation of VMATs (7). The 29 Kd 
protein is hypothesized to be a truncated form lacking transport activity, as vesicular 
transporters usually have 12 membrane-spanning domains that yield molecular weights 
greater than 50 Kd (6).      
 
Time-course of Serotonin Uptake by hVMAT1 Variants 
The time course of radiolabeled serotonin uptake by protein extracts from cells 
transfected with  hVMAT1-a (Thr4 Ser98 Ile136) or hVMAT-98Thr (Thr4 Thr98 Ile136) 
or hVMAT-1 4Pro (Pro4 Ser98 Ile136) increased steadily and was approximately linear 
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over at least 5 min (Fig. 4).  Serotonin uptake by protein from wild type cells did not 
increase over time.  There were no statistical differences in the uptake of serotonin by 
hVMAT1a  and hVMAT-98Thr over 15 minutes, but the time course of radiolabeled 
serotonin uptake by hVMAT1- 4Pro differed significantly from both hVMAT1-a and 
hVMAT-98Thr.  A quantitative comparison of serotonin uptake measured at 5 min is 
shown in Fig. 5.   
 
Inhibition of hVMAT1 Variants by Reserpine  
 The first studies of response to inhibitors were performed with the VMAT 
inhibitor reserpine, and these studies were used to establish methodology for subsequent 
assays.  Preliminary inhibition curves were performed with extracts from 7 transfections   
of each of two variants.  These data (not shown) identified occasional spurious results 
demonstrating the necessity for additional repetition to verify the reproducibility of results.   
 Fig. 6 illustrates average inhibition curves for effects of reserpine on radiolabeled 
serotonin uptake by the variant protein cell extracts. The average IC50 (Table 3) of 
reserpine inhibition was significantly greater for the hVMAT with a 4Pro/Ser98 (Pro4 
Ser98 Ile136) than for the 4Thr/98Thr (Thr4 Thr98 Ile136) (P < 0.05).  Reserpine 
inhibition of  hVMAT1-a (Thr4 Ser98 Ile136) and hVMAT-98Thr (Thr4 Thr98 136 Ile) 
did not differ significantly.   
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Inhibition of Serotonin Uptake by hVMAT1 Variants by Dopamine 
Dopamine inhibition of serotonin uptake by protein extracts from cells transfected 
with expression vectors carrying the three different haplotypes (Fig. 7 and Table 3) did not 
differ significantly.   
 
Saturation Kinetics of Serotonin Uptake by Human VMAT1 Variants 
Saturation studies were performed at 1.5 min in an attempt to achieve initial 
velocity of transport.  As shown in Fig. 8 and Table 4, the transport Vmax of the hVMAT-
1a (Thr4 Ser98 Ile136) and hVMAT-98Thr (Thr4 Thr98 Ile136) variants was greater than 
that of hVMAT-4Pro (Thr4 Ser98 Ile136).  Although the transport Km of the 4Pro/Ser98 
variant protein was slightly lower than that of the other variants, the difference was not 
significant (Table 4).  In time course studies performed with 20 nM radiolabeled serotonin 
the variants  hVMAT-1a (Thr4 Ser98 Ile136) and hVMAT-98Thr (Thr4 Thr98 Ile136) did 
not differ significantly, and with saturating concentrations of radiolabelled serotonin, the 
transport Vmax of these variants also did not differ significantly (Fig. 8 and Table 4).   
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Discussion 
This study provides new information on the functional and biochemical effects of 
single nucleotide polymorphisms in the human VMAT1 gene that have been linked to 
psychiatric disorders.  This information is anticipated to provide clues to mechanisms that 
account for linkage of these SNPs to schizophrenia and other psychiatric disorders.  
Genetic linkage studies performed by several laboratories suggest that the proline at 
position 4 is associated with increased susceptibility to schizophrenia in Han Chinese and 
western European populations (2;3;14).  The results of the present study indicate that the 
hVMAT-1 4Pro/98Ser haplotype is associated with a decrease in transport activity 
compared with other haplotypes in this study (Fig. 4 and 5), This finding is consistent with 
evidence that reduced storage of monoamines in the brain and adrenal medulla and 
potential disruption of regulatory mechanisms of adrenal-hypothalamic-pituitary 
interactions will increase susceptibility to mood and behavioral disorders and potential 
changes in cognitive functions (15).  The transport Km of this haplotype was slightly but 
not significantly lower than that of the other variants.  It appears unlikely, therefore, that a 
higher affinity for substrate could compensate for the reduced maximal function of the 
4Pro variant.  Furthermore, there were no detectable differences among the variants in 
response to dopamine inhibition of serotonin uptake.   
There were no significant differences in transport function between the 4Thr/98Thr 
and 4Thr/98Ser haplotypes.  Although the SNP coding for either a threonine 98 or a serine 
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98 has been linked to schizophrenia in both Chinese and Japanese populations (3;20), it is 
a different allele in each population that is more frequent in schizophrenic patients.  This 
raises the possibility that other factors in combination with a specific 98 amino acid may 
increase susceptibility to schizophrenia.  The more prominent effect on transport of the 
SNP coding for a 4 proline may be because of its location in the cytoplasmic N-terminus.  
Additionally, there is evidence for phosphorylation for VMATs (7), and whereas both 
threonine and serine can be phosphorylated, proline is not a substrate for phosphorylation. 
It is clear that changes in VMAT1 in brain could alter storage of monoamine 
neurotransmitters, but an additional hypothesis linking changes in VMAT1 to mood and 
behavioral changes is based on the function of VMAT1 in storing epinephrine in vesicles 
in the adrenal medulla.  These vesicles are primed at the plasma membranes to be 
exocytosed when triggered. VMAT-1 is the major vesicular monoamine transporter that 
functions in adrenal medullary storage and regulated release of catecholamines, 
particularly epinephrine,  in rodents as well as humans (7). Decreased function of VMAT-1 
in the adrenal medulla will reduce storage and release of adrenal catecholamines, which 
may produce a deficiency of the rapid mechanism responsible for alleviating hypoglycemia 
during fasting or stress (4).  Assuming that the 4Pro haplotype would cause less 
epinephrine to be stored and released, less epinephrine will be available to stimulate 
mechanisms that alleviate hypoglycemia.  Persistent hypoglycemia during epinephrine 
deficiency will stimulate increased release of corticotropin-releasing hormone (CRH), 
adrenocorticotropic hormone (ACTH) and corticosteroids, and glucagon.  Increased 
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production of CRH and continuing elevation of plasma corticosteroids increase 
susceptibility to depression and anxiety (15) and alter cognitive neural pathways in the 
hippocampus and striatum (15;21) 
In summary, this study suggests that a proline at position 4 in hVMAT1 causes a 
modest reduction in VMAT1 transport function and alters its response to the inhibitor 
reserpine.  In contrast, the exchange of a threonine for a serine at position 98 in the protein 
appears to have little effect on transporter function.  Additional study is needed to clarify 
the functional consequences of the Thr136Ile polymorphism in hVMAT1 and 
combinations of amino acid changes at the 4, 98, and 136 positions.  
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Results Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Immunoreactive human VMAT-1 assayed by western blotting. Beta actin 
loading controls are shown below each lane. Total protein (2 µg per lane) was separated by 
SDS-PAGE on 10 % gels.  Lane 1= COS1 cells+hVMAT1a (4Thr/98Ser/136Ile);  2 = 
COS1+hVMAT1 (4Thr/98Thr/136Ile); 3 = COS1+hVMAT1 (4Pro/98Ser/136Ile); 4 = 
COS WT cells. The arrow indicates a 63 kD protein hypothesized to be the major active 
hVMAT1 protein.  
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Figure 4. Time course of serotonin uptake by human VMAT1 variants. Uptake of 
radiolabeled serotonin ([3H] 5HT) by protein extracts from wild type (WT) COS1 cells 
or cells transfected with expression vectors carrying human VMAT1 with 
polymorphisms coding for a threonine or serine at amino acid 98 and threonine or 
proline at amino acid 4.  The data represent the mean ± S.E. of 3 transfections for each 
variant.  Uptake of each variant was significantly greater than that of WT cells at each 
time point.  Uptake by hVMAT1 with a 4Pro was significantly less than that of the 
hVMAT1a98Ser and hVMAT98Thr by two-way ANOVA and Newman Keuls’ post-
hoc test (* P < 0.01). 
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Figure 5.  Quantitative comparison of serotonin uptake at 5 minutes by human 
VMAT1 variants. Comparison of radiolabeled serotonin ([3H] 5HT) by protein extracts 
from wild type (WT) COS1 cells and cells transfected with expression vectors carrying  
human VMAT1 with polymorphisms coding for a threonine or serine at amino acid 98 and 
a threonine or proline at amino acid 4.  Each bar represents the mean ± S.E. of 9-12 
replicates from 3-7 transfections for each variant measured at 5 min incubation. All are 
significantly different from wild type by one-way ANOVA and Newman Keuls’ post-hoc 
test. * P < 0.01 compared to 4 PRO/98SER. 
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Figure 6.  Reserpine inhibition of serotonin uptake by human VMAT1 variants.  
Protein extracts from cells transfected with expression vectors carrying human VMAT1 
DNA coding for the different haplotypes were incubated for 5 minutes with vehicle or 5-6 
concentrations of reserpine and tritium labeled serotonin. Each curve represents the 
average of 3-5 curves run on 3-5 transfections of each variant with wild type values 
subtracted. The average IC50 (Table 3) of reserpine inhibition was significantly greater for 
the hVMAT1 with a 4Pro/Ser98 (Pro4 Ser98 Ile136) than for the 4Thr/98Thr (Thr4 Thr98 
Ile136) based on 95% confidence limits of the best fit non-linear regressions. 
.  
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Figure 7.  Dopamine inhibition of serotonin uptake by human VMAT1 variants.  
Protein extracts from cells transfected with expression vectors carrying human VMAT1 
DNA coding for the different haplotypes were incubated for 5 minutes with vehicle or 5-6 
concentrations of dopamine and tritium labeled serotonin. Wild type values were 
subtracted from each point. The average IC50 (Table 3) of dopamine inhibition of serotonin 
uptake did not differ significantly among the three protein variants.  
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Figure 8.  Saturation kinetics of serotonin uptake by human VMAT1 variants. Curves 
illustrate uptake of 1.0:1.2 radiolabeled:unlabeled serotonin over 1.5 min by protein 
extracts from COS1 cells transfected with expression vectors carrying human VMAT1 
with polymorphisms coding for a threonine or serine at amino acid 98 and threonine or 
proline at amino acid 4.  Each data point represents the mean ± S.E. of 3-5 replicates from 
3 transfections per variant with wild type values subtracted.  Transport Km and Vmax 
values are in Table 4.   
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Table 3. Inhibition of Human VMAT1 Variant Uptake of Serotonin 
 
hVMAT1 
Haplotype 
Reserpine IC50  
(nM) 
Mean ± S.E 
Dopamine IC50 
(µM) 
  Mean ± S.E. 
4Thr/98Ser/ 169  ± 29 0.92 ± 0.22 
4Thr/98Thr 116 ± 31 1.07 ± 0.21 
4Pro/98Ser    271 ± 34* 0.70 ± 0.15 
 
*P  ≤ 0.05 compared to the IC50 of the 4Thr/98Thr haplotype based on 95% confidence 
limits of the best fit non-linear regression. 
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Table 4.  Saturation Kinetics of Serotonin Transport 
by Human VMAT1 Variants 
 
hVMAT1  
Haplotype 
Km 
µM 
Mean ± S.E 
Vmax 
nmol/1.5 min(mg protein-1) 
Mean ± S.E 
4Thr/98Ser/ 1.76 ± 0.48   31.53   ±   3.09 
4Thr/98Thr 1.68 ± 0.48            38.00   ±   3.53 
4Pro/98Ser 0.57 ± 0.22     19.17    ±   2.13* 
                  
*P ≤0.05 compared to 4 Thr/98Ser and 4Thr98Thr based on 95% confidence limits of the 
best fit non-linear regression. 
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